Siemens Healthineers Released New D-Dimer Assay
Diagnostic labs can now use the updated assay to process venous thromboembolism testing with greater workflow efficiency.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you trust that new medical testing technology in your area significantly improves diagnostic accuracy?
Siemens Healthineers launched the Innovance D-Dimer 2.0 assay, which recently secured FDA 510(k) clearance and a CE mark. The test supports clinical assessment for venous thromboembolism, including pulmonary embolism and deep vein thrombosis.
Why it matters
The new assay is designed to assist clinical laboratories facing high test volumes and staffing constraints by streamlining urgent testing processes. It provides a more efficient tool for monitoring disseminated intravascular coagulation.
The Innovance D-Dimer 2.0 assay received FDA 510(k) clearance, marking the latest iteration of the diagnostic test. It integrates with current CN-3000 and CN-6000 hemostasis systems used in clinical settings.
The players
Siemens Healthineers
A global medical technology company that develops and manufactures diagnostic imaging, laboratory diagnostics, and advanced therapy systems.
The details
The assay utilizes ready-to-use reagents and controls to reduce manual intervention in diagnostic workflows. These features are intended to improve triage and facilitate faster treatment decision processes in urgent care environments. The system is specifically optimized for high-volume lab operations.
Timeline
October 6, 2026: The launch of the assay was confirmed.
Market Landscape
This release follows the established regulatory pattern of the FDA 510(k) premarket notification process for medical device updates. It aligns with broader industry trends toward integrating workflow-oriented diagnostics to manage capacity bottlenecks in clinical settings.
Laboratory operators should evaluate whether their existing CN-3000 or CN-6000 systems are configured to integrate these new reagents. Managers should monitor staffing utilization metrics to determine if the assay's workflow features reduce the burden on personnel during peak hours.
The takeaway
The addition of this assay signals a focus on mitigating labor-related bottlenecks through technological automation. Operators should track the throughput improvements of their current hemostasis systems to determine if an upgrade to version 2.0 provides a measurable reduction in turnaround times.
Further reading
For more on evolving diagnostic standards, see our Healthcare section.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you trust that new medical testing technology in your area significantly improves diagnostic accuracy?
